244 results about "Influenza C Virus" patented technology

Described in this application are attenuated strains of avian influenza virus containing temperature sensitive mutations in addition to a genetic tag in the PB1 gene. The attenuated viruses are useful as avian and mammalian vaccine for protective immunity against homologous and heterologous lethal challenges with influenza virus. A genetically modified avian influenza virus backbone is described which can be used as a master donor strain for the generation of live attenuated vaccines for epidemic and pandemic influenza.

Described herein are chimeric influenza virus gene segments and nucleic acid sequences encoding such chimeric influenza virus gene segments. A chimeric influenza virus gene segment described herein comprises packaging signals found in the non-coding and coding regions of one type of influenza virus gene segment and an open reading frame of a different type of influenza virus gene segment or fragment thereof. Also described herein are recombinant influenza viruses comprising two or more chimeric influenza virus gene segments and the use of such viruses in the prevention and/or treatment of influenza virus disease.

The invention provides a polycyclic pyridone compound as well as pharmaceutical composition and an application thereof. Specifically, the polycyclic pyridone compound is a compound shown as the formula (I) or pharmaceutically acceptable salt, solvate or hydrate of the compound. The compound can be used for preparing drugs for preventing or treating infectious diseases of mammals, and is particularly used for preparing drugs for preventing, treating, relieving and/or treating orthomyxovirus infection such as influenza A virus, influenza B virus and influenza C virus.

An aspect of the present invention is directed towards DNA plasmid vaccines capable of generating in a mammal an immune response against a plurality of influenza virus subtypes, comprising a DNA plasmid and a pharmaceutically acceptable excipient. The DNA plasmid is capable of expressing a consensus influenza antigen in a cell of the mammal in a quantity effective to elicit an immune response in the mammal, wherein the consensus influenza antigen comprises consensus hemagglutinin (HA), neuraminidase (NA), matrix protein, nucleoprotein, M2 ectodomain-nucleo-protein (M2e-NP), or a combination thereof. Preferably the consensus influenza antigen comprises HA, NA, M2e-NP, or a combination thereof. The DNA plasmid comprises a promoter operably linked to a coding sequence that encodes the consensus influenza antigen. Additionally, an aspect of the present invention includes methods of eliciting an immune response against a plurality of influenza virus subtypes in a mammal using the DNA plasmid vaccines provided.

Antimicrobial compositions containing two or more antiviral agents coupled to a polymer and methods of making and using the compositions, are described herein. In one embodiment, two or more antiviral agents are covalently coupled to the polymer. Suitable antiviral agents include, but are not limited to, sialic acid, zanamivir, oseltamivir, amantadine, rimantadine, and combinations thereof. The polymer is preferably a water-soluble, biocompatible polymer. Suitable polymers include, but are not limited to, poly(isobutylene-alt-maleic anhydride) (PIBMA), poly(aspartic acid), poly(l-glutamic acid), polylysine, poly(acrylic acid), plyaginic acid, chitosan, carboxymethyl cellulose, carboxymethyl dextran, polyethyleneimine, and blends and copolymers thereof. In another embodiment, the compositions contain a physical mixture of polymer containing one antiviral agent and polymer containing a second antiviral agent. The compositions can be formulated for enteral or parenteral administration. Suitable oral/intranasal dosage forms include, but are not limited to, tablets, capsules, solutions, suspensions, emulsions, syrups, and lozenges. Suitable dosage forms for parenteral administration include, but are not limited to, solutions, suspensions, and emulsions. The compositions described herein are effective at treating a variety of infections, including viral infections such as influenza, while inhibiting or preventing the development of microbial resistance.

The invention provides compositions of inactivated influenza virus that can be used as vaccines and immunological compositions useful for inhibiting, preventing and treating influenza.

Provided are processes for the preparation of compositions enriched in phenolic compounds from a crude plant extract. One process includes a novel column purification step using a polymer resin that releasably adsorbs the phenolic compounds but does not retain polar non-phenolic compounds, wherein the resin comprises aromatic rings substituted with one or more electron-withdrawing groups. This invention also includes compositions enriched in phenolic compounds. This invention encompasses methods of using the phenolic-enriched compositions for treating warm-blooded animals, including humans, infected with paramyxovaridae such as respiratory syncytial virus, orthomyoxovaridae such as influenza A, B, and C, parainfluenza, Herpes viruses such as HSV-1 and HSV-2, and Flaviviruses such as West Nile Virus, and for treating inflammation such as caused by arthritis, stress and digestive disease. The compositions are also useful as meat additives to inhibit food-borne pathogens.

The invention relates to the field of influenza virus and the vaccination against flu. The invention provides a conditionally defective influenza virus particle having seven different influenza nucleic acid segments. The invention also provides a conditionally defective influenza virus particle lacking an influenza nucleic acid segment selected from the group of segments essentially encoding acidic polymerase (PA), the basic polymerase 1 (PB1) and the basic polymerase 2 (PB2). In particular, the invention provides defective influenza virus particles having seven different influenza nucleic acid segments and lacking an influenza nucleic acid segment essentially encoding acidic polymerase. Furthermore, the invention provides use of a composition comprising a defective influenza virus particle according to the invention for the production of a pharmaceutical composition directed at generating immunological protection against infection of a subject with an influenza virus, and provides a method for generating immunological protection against infection of a subject with an influenza virus comprising providing a subject in need thereof with a composition comprising such defective influenza virus particle.

The subject invention provides materials and methods for treating various health conditions, including the prevention and/or treatment of a viral infection. In a preferred embodiment, a cysteamine compound is administered to a subject to treat an influenza virus infection. More preferably, a cysteamine compound is administered to a subject to treat influenza A, influenza B, influenza C virus infections, including avian influenza virus subtypes (such as H5N1 avian influenza virus).

The invention is related to a method for selecting an influenza virus for growth on tissue culture cells to produce a tissue-culture adapted viral isolate. The invention also includes vaccines produced from the isolate.

The invention relates to nucleic acid composition, a detection kit for an influenza virus and a micro-fluidic chip. The nucleic acid composition comprises detection primer pairs, wherein the detection primer pairs comprise at least two of the following primer pairs: an influenza A primer pair, an influenza B primer pair, an influenza C primer pair, an influenza A H1 primer pair, an influenza A H3 primer pair, an influenza A H5 primer pair, an influenza A H7 primer pair, an influenza A H9 primer pair, an influenza A N9 primer pair and a high-pathogenicity influenza A H7N9 primer pair. According to the nucleic acid composition, interference between the primers and probes can be avoided, at least two influenza viruses are detected simultaneously once, and detection sensitivity can reach 100 copies/mL.

The present invention provides compositions for use as vaccines against the influenza virus, and rapid methods of producing such compositions. The composition include i) at least one peptide derived from an influenza virus, wherein the peptide is fused to a capsid protein derived from a plant virus forming a recombinant capsid fusion peptide and ii) at least one isolated antigenic protein or protein fragment derived from a human or avian influenza virus. The isolated antigenic protein or protein fragment derived from the human or avian influenza virus can be conjugated to the surface of the recombinant capsid fusion peptide.

The invention provides a method for producing influenza viruses in large scale by using a bioreactor, which comprises the following steps of: (1) inoculating passage cell suspension into a vector tank, and setting the parameters of the bioreactor to perform a cell adsorption and culture process, wherein a serum culture medium is used in the cell adsorption and culture process; (2) when cells are grown to proper density, rinsing the cells to remove serum components, inoculating influenza virus liquid into the vector tank, and setting the parameters of the bioreactor to perform a virus adsorption and propagation process, wherein a serum-free culture medium containing TPCK (tosyl-L-phenylalanine chloromethyl ketone) pancreatin is used in the virus adsorption and propagation process; and (3) harvesting the virus liquid. The method has the advantage that: the high-titer virus liquid can be obtained by adopting the tide type bioreactor and using the passage cells for propagating the influenza viruses. The method overcomes the defects of the traditional transfer bottle culture and other bioreactors, and can continuously produce high-titer viruses in large scale.

A method for producing influenza virus on large scale is provided. A method for propagating influenza virus which comprises, after removing or decreasing a trypsin inhibitor secreted into culture of MDCK cells (cell line derived from dog kidney) by washing with a culture medium or a buffer, inoculating influenza virus into said cells and culturing said influenza virus-inoculated cells in a culture medium supplemented with trypsin.

The invention belongs to the antiviral field of medical chemistry and relates to a novel pyridine derivative shown in a formula (I), a stereisomer, pharmaceutical salt, a solvent compound or a crystalof the pyridine derivative and an application of the pyridine derivative and the stereisomer, pharmaceutical salt, the solvent compound or the crystal in preparing drugs for preventing or treating viral infection diseases such as influenza A and/or influenza B, particularly in preparing a cap dependent endonuclease inhibitor in preventing or treating influenza A and/or influenza B viral infectiondiseases. The compound has remarkable activity for inhibiting influenza endonuclease and influenza DNA, can be independently used or can be combined with a neuraminidase inhibitor, nucleoside medicines, a PB2 inhibitor, a PB1 inhibitor, an M2 inhibitor or other anti-influenza drugs, the influenza infection time is notably shortened, the death rate is remarkably reduced, and the pyridine derivative has very good clinical application prospects.

The invention discloses a production method for vaccines of avian influenza virus and other influenza virus such as swine influenza, dog influenza and equine influenza, which comprises the following steps of: (1) transfer of culture and cultivation of vaccine-made cells; (2) reproduction of vaccine-made virus seeds; (3) microcarrier suspension culture of MDCK cells in a bioreactor; (4) reproduction of vaccine-made virus liquid; and (5) harvest of the virus liquid. The production method has the advantages of reducing the production cost greatly and improving the yield and quality of the vaccines obviously, along with short production period, no restriction to raw material supply, small occupied area, easy and quick expansion of production scale, light environmental pollution, easy processing, high automaticity, low employment and easy realization of balanced and stable quality.

The present disclosure relates to a real-time fluorescence multiplex PCR primer probe for seven common respiratory system influenza virus pathogens and a kit. Seven influenza viruses are influenza A virus, influenza B virus, parainfluenza virus type I, parainfluenza virus type II, parainfluenza virus type III, respiratory syncytial virus and adenovirus. The present disclosure also provides a kit for multiplex fluorescence quantitative PCR detection of the seven influenza viruses, and the kit includes the primer probe set. The kit significantly improves the sensitivity, specificity, and simplicity of detection of the common respiratory system pathogens.

The invention discloses applications of dihydromyricetin in preparation of anti-influenza virus drugs, wherein influenza virus is influenza A virus, preferably H1N1, H3N2, H5N1, H7N1, H7N2, H7N3, H7N7, H7N9, H9N2 or H10N8. According to the present invention, the anti-influenza A virus action mechanism of the dihydromyricetin is that the activity of the ribonucleoprotein complex vRNP is inhibited by binding the dihydromyricetin to the PB2cap protein so as to prepare the drugs for prevention and treatment of influenza, wherein the binding loci of the dihydromyricetin and the PB2cap protein are site-432 histidine (His432), site-357 histidine (His357), site-404 phenylalanine (Phe404), site-323 Phenylalanine (Phe323), site-361 glutamic acid (Glu361), site-376 lysine (Lys376), site-363 phenylalanine (Phe363), and site-429 asparagine (Asn429).